WO2006031996A3 - Targeting viruses using a modified sindbis glycoprotein - Google Patents
Targeting viruses using a modified sindbis glycoprotein Download PDFInfo
- Publication number
- WO2006031996A3 WO2006031996A3 PCT/US2005/033062 US2005033062W WO2006031996A3 WO 2006031996 A3 WO2006031996 A3 WO 2006031996A3 US 2005033062 W US2005033062 W US 2005033062W WO 2006031996 A3 WO2006031996 A3 WO 2006031996A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell
- interest
- viruses
- targeting viruses
- modified sindbis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16741—Use of virus, viral particle or viral elements as a vector
- C12N2710/16743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16741—Use of virus, viral particle or viral elements as a vector
- C12N2710/16745—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20261—Methods of inactivation or attenuation
- C12N2760/20262—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
Abstract
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60957304P | 2004-09-14 | 2004-09-14 | |
US60/609,573 | 2004-09-14 | ||
US61479104P | 2004-09-30 | 2004-09-30 | |
US60/614,791 | 2004-09-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006031996A2 WO2006031996A2 (en) | 2006-03-23 |
WO2006031996A3 true WO2006031996A3 (en) | 2006-07-06 |
Family
ID=36060714
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/033062 WO2006031996A2 (en) | 2004-09-14 | 2005-09-14 | Targeting viruses using a modified sindbis glycoprotein |
Country Status (2)
Country | Link |
---|---|
US (1) | US7429481B2 (en) |
WO (1) | WO2006031996A2 (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2351844T3 (en) | 2003-04-29 | 2014-09-22 | Sarepta Therapeutics Inc | Preparations for enhancing transport and antisense efficiency of nucleic acid analog in cells |
US20050288246A1 (en) | 2004-05-24 | 2005-12-29 | Iversen Patrick L | Peptide conjugated, inosine-substituted antisense oligomer compound and method |
AU2006252406B2 (en) * | 2005-06-01 | 2012-05-17 | California Institute Of Technology | Method of targeted gene delivery using viral vectors |
US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
PT2520168E (en) | 2006-07-21 | 2014-04-29 | California Inst Of Techn | Targeted gene delivery for dendritic cell vaccination |
WO2008144067A1 (en) * | 2007-05-21 | 2008-11-27 | Board Of Regents, University Of Texas System | Methods and compositions for treatment of cancer using oncolytic rsv activity |
US20100016215A1 (en) | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
WO2010005696A1 (en) * | 2008-06-16 | 2010-01-14 | Eden Therapeutics Inc. | Diagnosis and treatment of tumors and metastases |
US8481297B2 (en) * | 2009-01-08 | 2013-07-09 | Yale University | Compositions and methods of use of an oncolytic vesicular stomatitis virus |
PL2456786T5 (en) * | 2009-07-24 | 2017-10-31 | Immune Design Corp | Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein |
US20120171246A1 (en) | 2009-09-10 | 2012-07-05 | Yale University | Immunization to reduce neurotoxicity during treatment with cytolytic viruses |
WO2011056993A1 (en) | 2009-11-04 | 2011-05-12 | Yale University | Compositions and methods for treating cancer with attenuated oncolytic viruses |
ES2816898T3 (en) * | 2010-05-13 | 2021-04-06 | Sarepta Therapeutics Inc | Compounds that modulate the signaling activity of interleukins 17 and 23 |
US9951117B2 (en) | 2010-09-02 | 2018-04-24 | Mayo Foundation For Medical Education And Research | Vesicular stomatitis viruses |
JP5944901B2 (en) * | 2010-09-02 | 2016-07-05 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | Vesicular stomatitis virus |
US9161948B2 (en) | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
EP2807180B1 (en) | 2012-01-24 | 2018-03-28 | InterK Peptide Therapeutics Limited | Peptide agents for cancer therapy |
US9713635B2 (en) | 2012-03-30 | 2017-07-25 | Immune Design Corp. | Materials and methods for producing improved lentiviral vector particles |
US8323662B1 (en) | 2012-03-30 | 2012-12-04 | Immune Design Corp. | Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein |
EA038702B1 (en) | 2012-03-30 | 2021-10-07 | Иммьюн Дизайн Корп. | Lentiviral vector particles having improved transduction efficiency for cells expressing dc sign |
WO2015077714A1 (en) | 2013-11-22 | 2015-05-28 | Yale University | Chimeric vsv virus compositions and methods of use thereof for treatment of cancer |
EP3302489A4 (en) | 2015-06-04 | 2019-02-06 | Sarepta Therapeutics, Inc. | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
HUE059843T2 (en) | 2016-12-19 | 2023-01-28 | Sarepta Therapeutics Inc | Exon skipping oligomer conjugates for muscular dystrophy |
CA3147615A1 (en) | 2018-07-17 | 2020-01-23 | Yale University | Methods for treatment of cancer using chikungunya-vsv chimeric virus |
WO2021034710A2 (en) * | 2019-08-16 | 2021-02-25 | Mayo Foundation For Medical Education And Research | Chimeric vesiculoviruses and methods of use |
CA3235865A1 (en) * | 2021-10-25 | 2023-05-04 | Genvivo, Inc. | Compositions and methods for therapeutic or vaccine delivery |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5689331A (en) * | 1995-12-08 | 1997-11-18 | General Electric Company | Laser apparatus with wander correction |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6432699B1 (en) * | 1997-03-28 | 2002-08-13 | New York University | Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A |
EP1227828A1 (en) * | 1999-11-12 | 2002-08-07 | Oncolytics Biotech, Inc. | Viruses for the treatment of cellular proliferative disorders |
-
2005
- 2005-09-14 US US11/227,778 patent/US7429481B2/en not_active Expired - Fee Related
- 2005-09-14 WO PCT/US2005/033062 patent/WO2006031996A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5689331A (en) * | 1995-12-08 | 1997-11-18 | General Electric Company | Laser apparatus with wander correction |
Non-Patent Citations (6)
Also Published As
Publication number | Publication date |
---|---|
WO2006031996A2 (en) | 2006-03-23 |
US7429481B2 (en) | 2008-09-30 |
US20060127981A1 (en) | 2006-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006031996A3 (en) | Targeting viruses using a modified sindbis glycoprotein | |
HK1083314A1 (en) | Use of artemisinin for treating tumors induced by oncogenic viruses and for treating viral infections | |
MX2019000252A (en) | Pseudotyped oncolytic viral delivery of therapeutic polypeptides. | |
EA201401096A1 (en) | COMBINATION THERAPY, INCLUDING ANTIHYALURONANE AGENT AND TAXAN, AIMED AT THE TREATMENT TARGET | |
WO2009006577A3 (en) | Compositions and methods for inhibiting ezh2 | |
WO2006103562A3 (en) | Endogenous retrovirus and proteins encoded by env gene as a target for cancer treatment | |
WO2012021512A3 (en) | Erythrocyte-binding therapeutics | |
WO2001053506A3 (en) | Virus strains for the oncolytic treatment of cancer | |
EP1767642A4 (en) | Construction of oncolytic adenovirus recombinant specifically expressing immune modulatory factor gm-csf in tumor cells and uses thereof | |
WO2015173208A3 (en) | Oligomers and oligomer conjugates | |
WO2011038160A3 (en) | Compositions and methods for silencing genes expressed in cancer | |
WO2003000928A3 (en) | Methods for identification of cancer cell surface molecules and cancer specific promoters, and therapeutic uses thereof | |
WO2008024302A8 (en) | Compounds for treating proliferative disorders | |
MY140829A (en) | Chimeric adenoviruses for use in cancer treatment | |
WO2008103763A3 (en) | Methods and compositions for cancer diagnosis and treatment based on nucleic acid methylation | |
WO2011103016A3 (en) | Compositions and methods for inhibiting ezh2 | |
WO2011071574A3 (en) | Monoclonal antibodies against glycoprotein of ebola sudan boniface virus | |
WO2008103380A3 (en) | Hepatitis b virus compositions and methods of use | |
IL258215B (en) | Antibody anti-mesothelin, nucleic acid encoding said antibody, vector comprising said nucleic acid, host cell comprising said vector, method of preparing said antibody, and pharmaceutical composition for treating cancer or tumor comprising the antibody | |
WO2012047317A3 (en) | Tumor specific antibodies and uses therefor | |
WO2010047830A3 (en) | Agents for hcv treatment | |
WO2008079973A9 (en) | Egfr binding peptides and uses thereof | |
AU2018273963A1 (en) | Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells | |
CA2876165C (en) | Particle-nucleic acid conjugates and therapeutic uses related thereto | |
WO2006109071A3 (en) | Vaccine against burkholderia infections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |